Active carriers should be treated firstly for their active hepatitis with nucleos(t)ide analogues (NAs), such as lamivudine, entecavir or adefovir-pipivoxil, and then with anti-TNF-α for their underlining disease [54]. This evidence concerns the gene TNF and hepatitis A virus infection.